Jerry Baty

Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA.

Frazier Management LLC (Frazier Healthcare Partners) is a venture capital subsidiary of Frazier & Co Inc. founded in 1991. The firm is headquartered in Seattle, Washington.

CoTherix, Inc. develops therapeutic products. Its ventavis product is a nebulizer delivered therapy for pulmonary artery hypertension, which restricts blood flow to the lungs. CoTherix markets its products in the US, Europe, and Australia. The company was founded in February, 2000 by Donald J. Santel and Gerard Turino and is located in Brisbane, CA.

Azelon Pharmaceuticals, Inc. develops biopharmaceutical drugs for the treatment of osteoporosis. It develops parathyroid hormone analogs for the treatment of bone diseases, which are characterized by deficits in bone formation, including osteoporosis, orthopedic conditions and renal bone disease. The company was founded by Paul Morley and Godfrey Marchand in 2000 and is headquartered in West Conshohocken, PA.

Intradigm Corp. develops drugs and therapies. Its RNAi therapeutic platform comprised of proprietary delivery technologies, potent siRNA sequences and innovative siRNA structural features. The company was founded by Puthupparampil Scaria, Martin C. Woodle, Wei-Wu He and Patrick Y. Lu in 2000 and is headquartered in Palo Alto, CA.

Calistoga Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. The company was founded by Michael W. Gallatin, Roger Ulrich and Neil Giese in March 2006 and is headquartered in Tumwater, WA.

Alnara Pharmaceuticals, Inc. develops and commercializes protein therapeutics for the treatment of metabolic diseases. It also develops liprotamase, a non-porcine pancreatic enzyme replacement therapy (PERT) for the treatment of exocrine pancreatic insufficiency (EPI). The company was founded by Christoph H. Westphal, Richard H. Aldrich and Alexy L. Margolin in 2008 and is headquartered in Boston, MA.

Incline Therapeutics, Inc. develops pharmaceutical products. The firm operates as hospital-focused specialty pharmaceutical company focused on the development of IONSYS (fentanyl iontophoretic transdermal system). The company was founded in 2009 and is headquartered in Seatle, WA.

Millendo Therapeutics US, Inc. engages in the development of novel treatment for adrenal cancer. It focuses on developing a portfolio of disease-modifying treatments for endocrine disorders caused by hormone dysregulation. The company was founded by Raili E. Kerppola, Julia C. Owens, and Gary D. Hammer in January 2012 and is headquartered in Ann Arbor, MI.

LifeSync Corp. engages in the development, marketing, and sale clean disposable electrocardiogram technologies. Its products are lifesync wireless ECG system, and disposable leadwear a wireless electrocardiogram data communication system appropriate for use in hospital and outpatient. The company was founded in 2000 and is headquartered in Coral Springs, FL.

Amunix, Inc. develops protein pharmaceuticals. It offers XTEN which is hydrophilic, unstructured, biodegradable polypeptides that impart a number of favorable properties upon the molecules to which they are attached. The company was founded by Volker Schellenberger and Willem Stemmer in 2006 and is headquartered in Mountain View, CA.

Sérum International, Inc. operates as online shoe store. It offers Birkenstock products as well as Tatami, Newalk, Papillio, Birki's, Birki kids, Birko, Birkenstock Comfort Shoes, FP by Birkenstock and Alpro lines. The company was founded in 1962 and is headquartered in Laval, Canada.

Rempex Pharmaceuticals, Inc. develops new therapies to combat the growing issue of antibiotic resistance. It focuses on the discovery and development of new antibacterial drugs to meet the clinical need created by multi-drug resistant bacterial pathogens. The company was founded by Daniel Burgess, Michael Dudley and Jeffery Loutit in June 2011 and is headquartered in San Diego, CA.

Part of Elanco Animal Health, Inc., ChemGen Corp. develops feed enzyme products that improve the efficiency of poultry, egg, and meat production. The company is based in Gaithersburg, MD. ChemGen was acquired by Elanco Animal Health, Inc. on February 17, 2012 for $206.90 million.

Alcresta Therapeutics, Inc. engages in the development of enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. It offers products designed to improve the delivery, digestion, and absorption of long-chain polyunsaturated fatty acids or LCPUFAs. The company was founded by Robert Gallotto and Dr. Alexey L. Margolin in 2011 and is headquartered in Newton, MA.

Acerta Pharma BV develops drugs for oncology and autoimmune diseases. It operates as a biotech company that combines technology platforms in drug discovery and development such as the covalent technology platform and the multiparametric phosphoflow cytometry platform. The company was founded by Allard Kaptein in 2012 and is headquartered in Oss, Netherlands.

Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA.

Seraxis Pte Ltd. provides biotechnology services. It offers a cure for insulin-dependent diabetes by replacing the lost insulin producing pancreatic cells with lab-grown cells, packaged within a device to protect the cells from immune rejection. The company was founded by William L. Rust in March 2013 and is headquartered in Singapore.

Mavupharma, Inc. engages development of non-nucleotide, conditional modulators of the STING pathway to treat cancer and infectious disease. The company was founded by W. Michael Gallatin, Brian K. Farmer, and Robert F. Baltera, Jr. and is headquartered in Kirkland, WA.

Amunix Pharmaceuticals, Inc. manufactures and fabricates drugs. The firm’s pipeline products are based on proprietary XTEN half-life extension, Antibody-XTEN-Drug Conjugate, ProTIA pro-drug and bispecific T-cell engager platform technologies. The company was founded by Willem P.C. Stemmer and Volker Schellenberger in 2006 and is headquartered in Mountain View, CA.

Lassen Therapeutics LLC operates as a therapeutic antibody company. It discovers and develops novel medicines to treat serious unmet medical needs. The company is headquartered in San Diego, CA.

Aegle Therapeutics Corp. is a biotechnology company, which isolates extracellular vesicles including exosomes (“EVs”) secreted by allogeneic bone marrow derived mesenchymal stem cells to treat dystrophic epidermolysis bullosa (“DEB”), a rare pediatric connective tissue disorder. Its EV therapy has the potential to demonstrate a safer, lower cost means of harnessing the regenerative healing power of stem cells without using the cells. The company was founded by Evangelos V. Badiavas, and Robert F. Williamson III in 2013 and is headquartered in Miami, FL.

Seraxis Holdings, Inc. functions as an investment holding private company. The company is based in Germantown, MD. The CEO of the company is William L Rust.

Enlaza Therapeutics, Inc. is a company that develops novel classes of protein therapeutics using their proprietary war-lock™ platform. The company is based in La Jolla, CA. The company's platform utilizes synthetic biology technology for site-specific covalent coupling driven by drug binding. Enlaza Therapeutics is pioneering the field of covalent biologics and aims to deliver more efficacious and safer treatments for patients. The CEO of the company is Sergio G. Duron.

Sudo Biosciences, Inc. is a biopharmaceutical company that focuses on designing and developing innovative medicines to improve the lives of patients. Sudo Biosciences is based in Menlo Park, CA, and has operations in other locations. The company's primary focus is on developing treatments that target the tyrosine kinase 2 (TYK2) pseudokinase domain, which is a crucial mediator in cytokine signaling pathways that have been associated with various immune-mediated inflammatory conditions. The CEO of the company is Scott A. Byrd.

Attovia Therapeutics manufactures a pipeline for bio therapeutics to immune-mediated diseases including cancer. The company is based in Sacramento, CA. Attovia Therapeutics was founded by Tao Fu and Tao Fu has been the CEO since incorporation.